Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 May;23(5):561–568. doi: 10.1111/j.1365-2125.1987.tb03092.x

Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

C A James, T G Mant, H J Rogers
PMCID: PMC1386192  PMID: 3109461

Abstract

The pharmacokinetics of mesna (sodium 2-mercaptoethane sulphonate) and its inactive disulphide, dimesna, were investigated using high performance liquid chromatography in six normal subjects following intravenous and oral administration of 800 mg mesna. The mean maximum mesna concentration after i.v. administration was 111 (s.d. +/- 28.3) nmol ml-1 and the mean maximum dimesna concentration was 183 (s.d. +/- 41.6) nmol ml-1. Following oral mesna dosing the mean peak mesna concentration was 19.6 (s.d. +/- 10.2) nmol ml-1 but mesna was only found in the plasma of five of the six subjects. The mean peak dimesna concentration was 22.5 (s.d. +/- 12.4) nmol ml-1. Following i.v. mesna administration, the mean half-life of mesna was 21.8 (s.d. +/- 3.1) min and total body clearance 1.23 (s.d. +/- 0.31) l kg-1 h-1. The mean half-life of dimesna was 1.17 (s.d. +/- 0.32) h. It was not possible to determine their half-lives after oral mesna administration. The mean mesna concentration in the 0-4 h urine collection was 9.6 (s.d. +/- 10.7; range 1.4-28.7) nmol ml-1 following i.v. mesna injection. After oral mesna the highest mesna concentration occurred in either the 0-4 or 4-8 h urine collections. The mean peak mesna concentration was 2.5 (s.d. +/- 1.7) mumol ml-1 (c.f. estimated uroprotective concentration of 1.7 mumol ml-1). The mean 4 h urinary clearance of the uroprotective species mesna was 0.413 (s.d. +/- 0.136) l kg-1 h-1. After both i.v. and oral mesna the urinary excretion of mesna is predominantly during the first 4 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
561

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brock N., Hilgard P., Pohl J., Ormstad K., Orrenius S. Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol. 1984;108(1):87–97. doi: 10.1007/BF00390979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brock N., Pohl J., Stekar J., Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol. 1982 Dec;18(12):1377–1387. doi: 10.1016/0277-5379(82)90143-2. [DOI] [PubMed] [Google Scholar]
  3. Brock N., Pohl J., Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer. 1981 Jun;17(6):595–607. doi: 10.1016/0014-2964(81)90261-9. [DOI] [PubMed] [Google Scholar]
  4. Brock N., Pohl J., Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol. 1981 Nov;17(11):1155–1163. [PubMed] [Google Scholar]
  5. Brock N., Stekar J., Pohl J., Niemeyer U., Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung. 1979;29(4):659–661. [PubMed] [Google Scholar]
  6. Burkert H. Clinical overview of mesna. Cancer Treat Rev. 1983 Sep;10 (Suppl A):175–181. doi: 10.1016/s0305-7372(83)80026-7. [DOI] [PubMed] [Google Scholar]
  7. Burkert H., Lücker P. W., Wetzelsberger N., Breuel H. P. Bioavailability of orally administered mesna. Arzneimittelforschung. 1984;34(11):1597–1600. [PubMed] [Google Scholar]
  8. Duran M., Aarsen G., Fokkens R. H., Nibbering N. M., Cats B. P., de Bree P. K., Wadman S. K. 2-Mercaptoethanesulfonate-cysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate--a pitfall in the diagnosis of sulfite oxidase deficiency. Clin Chim Acta. 1981 Mar 19;111(1):47–53. doi: 10.1016/0009-8981(81)90419-8. [DOI] [PubMed] [Google Scholar]
  9. ELLMAN G. L. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70–77. doi: 10.1016/0003-9861(59)90090-6. [DOI] [PubMed] [Google Scholar]
  10. Gobert J., Risack L., Close J. Etudes biochimiques, métaboliques et pharmacologiques d'un mucolytique: le Mestabron. Acta Anaesthesiol Belg. 1971;22(2):85–114. [PubMed] [Google Scholar]
  11. Ikeuchi I., Amano T. Simultaneous determination of 2-mercaptoethanesulfonate and its disulfide in human urine by isotachophoresis. Chem Pharm Bull (Tokyo) 1985 Jul;33(7):3016–3019. doi: 10.1248/cpb.33.3016. [DOI] [PubMed] [Google Scholar]
  12. James C. A., Rogers H. J. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1986 Oct 31;382:394–398. doi: 10.1016/s0378-4347(00)83550-1. [DOI] [PubMed] [Google Scholar]
  13. Jones M. S., Murrell R. D., Shaw I. C. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol. 1985 May;21(5):553–555. doi: 10.1016/0277-5379(85)90079-3. [DOI] [PubMed] [Google Scholar]
  14. Scheef W., Klein H. O., Brock N., Burkert H., Günther U., Hoefer-Janker H., Mitrenga D., Schnitker J., Voigtmann R. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep. 1979 Mar;63(3):501–505. [PubMed] [Google Scholar]
  15. Stuart-Harris R., Harper P. G., Kaye S. B., Wiltshaw E. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev. 1983 Sep;10 (Suppl A):163–164. doi: 10.1016/s0305-7372(83)80023-1. [DOI] [PubMed] [Google Scholar]
  16. Van Dyk J. J., Falkson H. C., Van der Merwe A. M., Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972 May;32(5):921–924. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES